Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 4, 2017, Pages 769-777

  Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

anti TNF therapy; complications; Crohn's disease; East Asia; inflammatory bowel disease; ulcerative colitis

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

EAST ASIAN; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MALIGNANT NEOPLASM; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINATION; VIRUS HEPATITIS; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOIMMUNE DISEASES; FAR EAST; HEPATITIS, VIRAL, HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; REMISSION;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOIMMUNE DISEASES; FAR EAST; GASTROINTESTINAL AGENTS; HEPATITIS, VIRAL, HUMAN; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; NEOPLASMS; REMISSION INDUCTION; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85016093965     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13612     Document Type: Review

References (70)

1. Cheon JH. Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. J. Gastroenterol. Hepatol. 2013; 28: 220–226.
2. Asakura H, Yao T, Matsui T et al. Efficacy of treatment with chimeric monoclonal antibody (infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 2001; 16: 763–769.
3. Lee KM, Jeen YT, Cho JY et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J. Gastroenterol. Hepatol. 2013; 28: 1829–1833.
4. Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea. Korean J. Gastroenterol. 2005; 46: 48–55.
5. Uchino M, Ikeuchi H, Bando T et al. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J. Gastroenterol. 2011; 17: 1174–1179.
6. Yang BL, Chen YG, Gu YF et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World J. Gastroenterol. 2015; 21: 2475–2482.
7. Kim EH, Kim DH, Park SJ et al. Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: a Korean, retrospective, single center study. Gut liver 2015; 9: 601–606.
8. Lee JH, Cheon JH, Jeon SW et al. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study. Inflamm. Bowel Dis. 2013; 19: 1833–1838.
9. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 2013; 72: 1613–1620.
10. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 2013; 72: 1605–1612.
11. Jung YS, Park DI, Kim YH et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J. Gastroenterol. Hepatol. 2015; 30: 1705–1712.
12. Smits LJ, Derikx LA, de Jong DJ et al. Clinical outcomes following a switch from remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J. Crohns Colitis 2016; 19 April 2016 [Epub] DOI: http://dx.doi.org/10.1093/ecco-jcc/jjw087.
13. Watanabe M, Hibi T, Lomax KG et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J. Crohns Colitis 2012; 6: 160–163.
14. Sohn IW, Kim ST, Kim B et al. Efficacy of adalimumab in Korean patients with Crohn's disease. Gut liver 2016; 10: 255–261.
15. Chang CW, Wei SC, Chou JW et al. Safety and efficacy of adalimumab for patients with moderate to severe Crohn's disease: the Taiwan Society Of Inflammatory Bowel Disease (TSIBD) STudy. Intestinal Res. 2014; 12: 287–292.
16. Hisamatsu T, Ueno F, Matsumoto T et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFalpha monoclonal antibodies. J. Gastroenterol. 2014; 49: 156–162.
17. Tanida S, Inoue N, Kobayashi K et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. Clin. Gastroenterol. Hepatol. 2015; 13: 940–948.e3.
18. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85–95; quiz e14-5.
19. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96–109.e1.
20. Amiot A, Hulin A, Belhassan M et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin. Res. Hepatol. Gastroenterol. 2016; 40: 90–98.
21. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am. J. Gastroenterol. 2012; 107: 1409–1422.
22. Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am. J. Gastroenterol. 2012; 107: 1051–1063.
23. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Health Patient Safe 2013; 5: 79–99.
24. Park SH, Kim YH, Lee JH et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev. Gastroenterol. Hepatol. 2015; 9 Suppl 1: 35–44.
25. Colombel JF, Sandborn WJ, Panaccione R et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 2009; 15: 1308–1319.
26. Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur. J. Clin. Pharmacol. 2014; 70: 907–914.
27. Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2009; 29: 921–927.
28. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 3372–3377.
29. Newton SM, Mackie SL, Martineau AR et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin. Vaccine Immunol. 2008; 15: 506–512.
30. Organization WH. Global tuberculosis report 2015. World Health Organization, 2015; 204.
31. Seong SS, Choi CB, Woo JH et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J. Rheumatol. 2007; 34: 706–711.
32. Jung SM, Ju JH, Park MS et al. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int. J. Rheum. Dis. 2015; 18: 323–330.
33. Byun JM, Lee CK, Rhee SY et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand. J. Gastroenterol. 2015; 50: 312–320.
34. Kim ES, Song GA, Cho KB et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J. Gastroenterol. 2015; 21: 3308–3316.
35. Fukuda R, Ishimura N, Ishihara S et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 390–399.
36. Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine 2014; 81: 478–484.
37. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000; 15: 1356–1361.
38. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212–2219.
39. Kim ES, Cho KB, Park KS et al. Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J. Clin. Gastroenterol. 2014; 48: 553–558.
40. Park SH, Yang SK, Lim YS et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm. Bowel Dis. 2012; 18: 2004–2010.
41. Leung WK, Liu K, Seto WK et al. Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience. J. Dig. Dis. 2013; 14: 596–603.
42. Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J. Crohns Colitis 2014; 8: 282–287.
43. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2010; 105: 501–523; quiz 24.
44. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59: 762–784.
45. Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009; 58: 1313–1315.
46. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2012; 107: 1460–1466.
47. Loras C, Gisbert JP, Saro MC et al. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J. Crohns Colitis 2014; 8: 1529–1538.
48. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2014; 8: 443–468.
49. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45: 1294–1297.
50. Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm. Bowel Dis. 2007; 13: 1450–1451.
51. Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig. Dis. Sci. 2013; 58: 1149–1156.
52. Shon HS, Choi HY, Kim JR et al. Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012. Clin. Mol. Hepatol. 2015; 21: 249–256.
53. Lee HS, Han CJ, Kim CY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area. Cancer 1993; 72: 2564–2567.
54. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006; 26: 1029–1039.
55. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593–1610.
56. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999; 59: 4516–4518.
57. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. 2010; 8: 268–274.
58. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390–399e1.
59. Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J. Gastroenterol. 2014; 49: 1299–1306.
60. Magro F, Peyrin-Biroulet L, Sokol H et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J. Crohns Colitis 2014; 8: 31–44.
61. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2009; 3: 47–91.
62. Sands BE, Cuffari C, Katz J et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2004; 10: 677–692.
63. Visser LG. TNF-alpha antagonists and immunization. Curr. Infect. Dis. Rep. 2011; 13: 243–247.
64. Fiorino G, Peyrin-Biroulet L, Naccarato P et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm. Bowel Dis. 2012; 18: 1042–1047.
65. Lee CK, Kim HS, Ye BD et al. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J. Crohns Colitis 2014; 8: 384–391.
66. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis. 2008; 47: 1328–1338.
67. Kantso B, Halkjaer SI, Thomsen OO et al. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. Vaccine 2015; 33: 5464–5469.
68. Launay O, Abitbol V, Krivine A et al. Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: a two-year prospective study. J. Crohns Colitis 2015; 9: 1096–1107.
69. deBruyn J, Fonseca K, Ghosh S et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm. Bowel Dis. 2016; 22: 638–647.
70. Rejmanek D, Hosseini PR, Mazet JA, Daszak P, Goldstein T. Evolutionary dynamics and global diversity of influenza A virus. J. Virol. 2015; 89: 10993–11001.